Cabergoline vs LGD-4033
FDA Approved vs Moderate Research
synergistic Mechanism-based · 55% LGD-4033 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
Cabergoline LGD-4033
Weight 451.60 Da 338.25 Da
Half-life ~63-69 hours ~24-36 hours
Type Ergoline-derived dopamine D2 receptor agonist Nonsteroidal selective androgen receptor modulator (C14H12F6N2O)
Key Benefits
Cabergoline
01 Potent suppression of prolactin levels, often normalizing them within days
02 Prevents and reverses prolactin-related gynecomastia from 19-nor compounds
03 Restores sexual function impaired by hyperprolactinemia (libido, erectile function, orgasm)
04 Long half-life (63-69 hours) allows convenient twice-weekly dosing
05 Significantly better tolerated than bromocriptine with fewer gastrointestinal side effects
06 Effective at shrinking prolactin-secreting pituitary tumors
07 Low doses required for bodybuilding prolactin management (0.25-0.5mg twice weekly)
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Side Effects
Cabergoline
Nausea (especially during initial doses; mitigated by taking with food)
Dizziness or lightheadedness
Headache
Nasal congestion or stuffiness
Fatigue or drowsiness
Orthostatic hypotension (feeling faint when standing up quickly)
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Contraindications
Known hypersensitivity to cabergoline or any ergot alkaloid
History of cardiac valvular disease or clinically significant valvular regurgitation
History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
Uncontrolled hypertension
Concurrent use of dopamine antagonists (antipsychotics, antiemetics acting on D2 receptors)
Severe hepatic impairment (cabergoline is extensively metabolized by the liver)
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Research Evidence
Cabergoline LGD-4033
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest — 2018
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.